The 5th Kidney Cancer Research Summit was a hybrid event hosted in Boston, MA in July 2023. As in previous editions, the conference attracted a wide representation of global thought leaders in kidney cancer spanning all stages of clinical and laboratory research. Sessions covered tumor metabolism, novel immune pathways, advances in clinical trials and immunotherapy, and progress toward biomarkers. The abstract presentations were published as a supplement in The Oncologist (https://academic.oup.com/oncolo/issue/28/Supplement_1). Aiming to be more concise than comprehensive, this commentary summarizes the most important emerging areas of kidney cancer research discussed and debated among the stakeholders at the conference, with relevant updates that have occurred since.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10836322 | PMC |
| http://dx.doi.org/10.1093/oncolo/oyad322 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhanced nano-LC-MS for analyzing dansylated oral cancer tissue metabolome dissolved in solvents with high elution strength.
Anal Chim Acta
February 2025
Department of Biochemistry and Molecular Biology, Chang Gung University, Taoyuan, 333, Taiwan; Clinical Proteomics Core Laboratory, LinKou Chang Gung Memorial Hospital, Taoyuan, 333423, Taiwan. Electronic address:
Background: Tissue metabolomics analysis, alongside genomics and proteomics, offers crucial insights into the regulatory mechanisms of tumorigenesis. To enhance metabolite detection sensitivity, chemical isotope labeling (CIL) techniques, such as dansylation, have been developed to improve metabolite separation and ionization in mass spectrometry (MS). However, the dissolution of hydrophobic derivatized metabolites in solvents with high acetonitrile content limits the use of liquid chromatography (LC) systems with small-volume reversed-phase (RP) columns.
View Article and Find Full Text PDFImplementation of patient-reported outcome dashboards within the electronic health record to support shared decision-making in serious chronic illness.
BMJ Open Qual
January 2025
Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Background: Attending to patient-reported outcomes (PROs) using data visualisation dashboards could enhance shared decision-making (SDM) and care delivery for serious chronic illnesses. However, few studies have evaluated real-world strategies and resulting implementation outcomes of PRO dashboards.
Method: From June 2020 to January 2022, we implemented an electronic health record (EHR)-integrated PRO dashboard for advanced cancer and chronic kidney disease.
Integrated RNA sequencing analysis and machine learning identifies a metabolism-related prognostic signature in clear cell renal cell carcinoma.
Sci Rep
January 2025
Department of Urology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
The connection between metabolic reprogramming and tumor progression has been demonstrated in an increasing number of researches. However, further research is required to identify how metabolic reprogramming affects interpatient heterogeneity and prognosis in clear cell renal cell carcinoma (ccRCC). In this work, single-cell RNA sequencing (scRNA-seq) based deconvolution was utilized to create a malignant cell hierarchy with metabolic differences and to investigate the relationship between metabolic biomarkers and prognosis.
View Article and Find Full Text PDFLeveraging explainable AI and large-scale datasets for comprehensive classification of renal histologic types.
Sci Rep
January 2025
Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 06591, Korea.
Recently, as the number of cancer patients has increased, much research is being conducted for efficient treatment, including the use of artificial intelligence in genitourinary pathology. Recent research has focused largely on the classification of renal cell carcinoma subtypes. Nonetheless, the broader categorization of renal tissue into non-neoplastic normal tissue, benign tumor and malignant tumor remains understudied.
View Article and Find Full Text PDFCan parenchymal volume analysis replace nuclear renal scans for split renal function before and after partial nephrectomy with warm ischemia?
Urol Oncol
January 2025
Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China; State Key Laboratory of Oncology in Southern China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China; State Key Laboratory of Oncology in Southern China, Guangzhou, P. R. China. Electronic address:
Article Synopsis
- The study evaluates parenchymal volume analysis (PVA) as a potential alternative to nuclear renal scan (NRS) for assessing split renal function (SRF) before and after partial nephrectomy (PN) with warm ischemia.
- Preoperatively, PVA showed a strong correlation with NRS findings, indicating its reliability for SRF assessment (49.4% vs. 50.0%, P = .501).
- Results suggest that while PVA is consistent with NRS preoperatively, the efficacy of PVA remains uncertain for post-operative SRF evaluation after PN, indicating a need for further investigation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!